stock market news, nxgen brands inc acquires exclusive license to utili 8386653890827187

GALT - Galectin Therapeutics Stock Trading

Galectin Therapeutics Inc.(NASDAQ: GALT) stock trading, description, contact, officers and directors.

About Galectin Therapeutics Inc.

Galectin is a clinical development stage biopharmaceutical company based in Norcross, Georgia, that is targeting fibrotic diseases and cancer with novel galectin inhibitor compounds. Galectins are a class of proteins made by many cells in the body and are important therapeutic targets because they are the mediators of fundamental biologic mechanisms in pathological processes. Galectin Therapeutics leverages its extensive scientific knowledge of galectins to advance their discovery program including research and discovery of new compounds. Through a relationship with a world class research program at the University of Georgia, the Company focuses on the discovery of new carbohydrate molecules that can be used in the therapy of diseases where galectin proteins play a major role including cancer and inflammatory and fibrotic disorders.

Stock Information

Galectin Therapeutics Inc. Company Name:

GALT Stock Symbol:

NASDAQ Market:

Galectin Therapeutics Inc. Website:

GALT - Galectin Therapeutics Stock Trading

GALT GALT Quote GALT Short GALT News GALT Articles GALT Message Board

Get GALT Alerts

News, Short Squeeze, Breakout and More Instantly...

GALT - Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020

NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., Chief Medical Officer, has been invited to make a presentation, entitled “Bela...
GALT - Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation

NORCROSS, Ga., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the passing of the two items on the Agenda for the 2020 Annual Meeting of Stockholders, that being the ...
GALT - Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders

NORCROSS, Ga., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of ...